Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn
Removes Sanofi Royalty Payments on Brain-Penetrant SAR442168
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.
You may also be interested in...
BTK Inhibitors could be a major advance multiple sclerosis therapy, and Biogen has bought into a potential challenger to Phase III frontrunner from Sanofi and Roche.
Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.
Sanofi R&D head John Reed says company has kept 95% of patients on its nearly 400 clinical trials and started 59 studies. Company has also stepped up collaborations and closed acquisitions, integrating employees remotely.